Clinical Report: Causal Links Between Type 2 Diabetes Mellitus and Site-Specific Cancers
Overview
This systematic review and meta-analysis of 42 Mendelian randomization studies found that type 2 diabetes mellitus (T2DM) causally increases the risk of pancreatic and endometrial cancers. Conversely, T2DM is associated with a decreased risk of gastric cancer, melanoma, and esophageal cancer, with no significant causal links identified for other cancer types.
Background
Type 2 diabetes mellitus (T2DM) is a chronic metabolic disorder characterized by insulin resistance and β-cell dysfunction, with rising global prevalence. Beyond classic complications, T2DM may influence cancer development through mechanisms such as hyperglycemia, hyperinsulinemia, and chronic inflammation. Observational studies have suggested associations between T2DM and various cancers, but confounding factors and reverse causality have limited causal inference. Mendelian randomization (MR) uses genetic variants as instrumental variables to infer causality, overcoming these limitations and providing more robust evidence on T2DM's role in cancer risk.
Data Highlights
Cancer Type
Odds Ratio (OR)
95% Confidence Interval (CI)
P-value
Direction of Association
Pancreatic Cancer
1.09
1.04-1.15
0.0007
Increased Risk
Endometrial Cancer
1.07
1.04-1.09
<0.00001
Increased Risk
Gastric Cancer
0.90
0.85-0.93
<0.00001
Decreased Risk
Melanoma
0.97
0.95-0.99
0.009
Decreased Risk
Esophageal Cancer
0.86
0.79-0.93
0.0002
Decreased Risk
Thyroid Cancer
Modest effect
Not clinically significant
NS
No significant association
Breast Cancer
Modest effect
Not clinically significant
NS
No significant association
Key Findings
T2DM significantly increases the risk of pancreatic cancer (OR 1.09, 95% CI 1.04-1.15).
T2DM significantly increases the risk of endometrial cancer (OR 1.07, 95% CI 1.04-1.09).
T2DM is associated with a decreased risk of gastric cancer (OR 0.90, 95% CI 0.85-0.93).
T2DM is associated with a decreased risk of melanoma (OR 0.97, 95% CI 0.95-0.99).
T2DM is associated with a decreased risk of esophageal cancer (OR 0.86, 95% CI 0.79-0.93).
No significant causal associations were found between T2DM and thyroid, breast, or ten other cancer types.
Clinical Implications
Clinicians should recognize that T2DM confers a tissue-specific cancer risk profile, notably increasing pancreatic and endometrial cancer risk. This underscores the importance of vigilant cancer screening and risk factor management in patients with T2DM. Conversely, the observed decreased risks for gastric, melanoma, and esophageal cancers warrant further investigation but should not alter current clinical practice without additional evidence.
Conclusion
This comprehensive MR meta-analysis clarifies that T2DM causally influences cancer risk in a tissue-specific manner, elevating risks for pancreatic and endometrial cancers while reducing risks for certain others. These findings enhance understanding of T2DM’s role in oncogenesis and may inform targeted prevention strategies.
